Document 0657
 DOCN  M9480657
 TI    Development of a human immunodeficiency virus-1 in vitro DNA synthesis
       system to study reverse transcriptase inhibitors.
 DT    9410
 AU    Borroto-Esoda K; Boone LR; Division of Virology, Wellcome Research
       Laboratories, Burroughs; Wellcome Co., Research Triangle Park, North
       Carolina 27709.
 SO    Antiviral Res. 1994 Apr;23(3-4):235-49. Unique Identifier : AIDSLINE
       MED/94317913
 AB    A Human immunodeficiency virus type-1 endogenous reverse transcriptase
       reaction was developed as an in vitro assay to study the inhibition of
       reverse transcription by antiviral compounds. Conditions were
       established for producing genomic length (-) strand DNA in high yields
       and measuring the inhibition of this transcript as the assay endpoint.
       In addition to genomic length (-) strand DNA, a novel segmented (-)
       strand product composed of a 6.0 kb reverse transcript of the 5' 2/3 of
       the viral RNA genome and a 3.5 kb reverse transcript of the 3' 1/3 was
       observed. The most prominent (+) strand product was the size expected
       for plus-strong stop DNA. Additional minor (+) strand species were also
       observed. The triphosphate form of the nucleoside analog inhibitor
       3'-azido-3'-deoxythymidine (RETROVIR, Zidovudine, AZT) and BI-RG-587
       (nevirapine), a non nucleoside inhibitor, were used to demonstrate the
       utility of the endogenous system for the analysis of reverse
       transcriptase inhibitors. In a standard reaction, synthesis of genomic
       length DNA was 50% inhibited by 0.1 microM AZTTP and 0.1 microM
       nevirapine.
 DE    DNA, Viral/*BIOSYNTHESIS/CHEMISTRY  Hydrogen-Ion Concentration
       HIV-1/*ENZYMOLOGY/METABOLISM  Pyridines/PHARMACOLOGY  Reverse
       Transcriptase/*ANTAGONISTS & INHIB/METABOLISM  Thymine
       Nucleotides/PHARMACOLOGY  Time Factors  Zidovudine/ANALOGS &
       DERIVATIVES/PHARMACOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).